Back to overview

New Review by Neumirna Team Explores Nrf2 as a Promising Target in Neurodegeneration

A new review article based on the work led by Clara Mayer and Lluís Riera-Ponsati from Neumirna Therepeutics has been published in Frontiers in Pharmacology.

The article examines the potential of targeting the Nrf2 pathway as a disease-modifying strategy in neurodegenerative disorders, including Alzheimer’s, Parkinson’s, ALS, and multiple sclerosis. Nrf2 is a transcription factor that plays a key role in regulating the body’s antioxidant and anti-inflammatory responses, as well as mitochondrial function. Understanding and effectively modulating this pathway could open new avenues for treatments aimed at slowing or preventing disease progression – an area where current options remain limited.

The review outlines the role of Nrf2 in the key pathological features shared across neurodegenerative diseases, including oxidative stress, protein aggregation, neuroinflammation, and mitochondrial dysfunction. It also discusses the current landscape of pharmacological approaches to activating the Nrf2 pathway and the challenges that remain.

The article provides a comprehensive overview of the field and suggests directions for future research in the development of novel therapies.

Publication
27.3.2025
Critical Review from Neumirna Team Published in Epilepsia
A new critical review by the Neumirna Therepeutic team has been published in Epilepsia, the leading journal in epilepsy research and clinical care.
Read full article
Publication
27.3.2025
New publication on RNA Biology
A comprehensive review on RNA Therapeutics for the treatment of neurmouscular disorders is out now on the latest issue of RNA Biology.
Read full article
Publication
27.3.2025
Review on Adenosine in the treatment of neuropathic pain published in the Scandinavian Journal of Pain
Henrik Klitgaard (Co-Founder, PhD) and Stine Norman-Hansen (Senior Scientist, PhD) authored this topical review together with leading pain expert, Prof. Lars Arendt-Nielsen.
Read full article